- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Normal phase chromatography.
Displaying page 1 of 1.
| EudraCT Number: 2019-001772-10 | Sponsor Protocol Number: 2016-06 | Start Date*: 2020-02-14 | |||||||||||
| Sponsor Name:Assistance Publique-Hôpitaux de Marseille | |||||||||||||
| Full Title: Phase I study of oral metronomic NAVELBINE® and HEMANGIOL®combination for children and teenagers with refractory/relapsing solid tumors | |||||||||||||
| Medical condition: Pediatric Solid tumor | |||||||||||||
|
|||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000105-23 | Sponsor Protocol Number: DYDRA001 | Start Date*: 2019-03-01 |
| Sponsor Name:UZ Brussel | ||
| Full Title: Oral dydrogesterone (OD) versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in IVF/ICSI: pharmacokinetics and the impact on the endometrium, the microbiota of the genital t... | ||
| Medical condition: Female infertility | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-000982-30 | Sponsor Protocol Number: 4993/15 | Start Date*: 2016-08-08 | |||||||||||
| Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
| Full Title: Personalized pharmacological treatment of chronic obstructive pulmonary disease based on phenotyping: interventional study | |||||||||||||
| Medical condition: Chronic obstructive pulmonary disease (COPD) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-001819-12 | Sponsor Protocol Number: CIS-COV | Start Date*: 2022-10-13 | |||||||||||
| Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
| Full Title: Cysteamine in association with standard therapy for the treatment of hospitalized patients with COVID-19 pneumonia: phase 2 study on safety of a new antiviral and direct therapy on the host | |||||||||||||
| Medical condition: Covid-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-002348-27 | Sponsor Protocol Number: PH2/052 | Start Date*: 2007-10-26 |
| Sponsor Name:Cancer Research UK | ||
| Full Title: A Cancer Research UK Phase II Proof of Principle Trial of the activity of the PARP-1 inhibitor, AG-014699, in known carriers of a BRCA 1 or BRCA 2 mutation with locally advanced or metastatic breas... | ||
| Medical condition: advanced or metastatic breast or ovarian carcinoma (proven carrier of a mutation in BRCA1 or 2 gene) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2016-001057-40 | Sponsor Protocol Number: 301OTC01 | Start Date*: 2017-03-14 | |||||||||||
| Sponsor Name:Ultragenyx Pharmaceutical, Inc. | |||||||||||||
| Full Title: A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults with Late-Onset OT... | |||||||||||||
| Medical condition: Ornithine transcarbamylase deficiency | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-004677-12 | Sponsor Protocol Number: RHYTHM | Start Date*: 2021-02-09 | |||||||||||
| Sponsor Name:UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE, METABOLICHE E NEUROSCIENZE | |||||||||||||
| Full Title: Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men. | |||||||||||||
| Medical condition: Aquired hypogonadotropic hypogonadism | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001128-31 | Sponsor Protocol Number: 13-23 | Start Date*: 2014-09-23 | |||||||||||
| Sponsor Name:Cancer Trials Ireland | |||||||||||||
| Full Title: Phase II Single-arm Study evaluating Neo-adjuvant (pre-radical radiotherapy) Abiraterone acetate (plus prednisolone) and Gonadotropin-Releasing Hormone (GnRH) agonist in high risk localised prostat... | |||||||||||||
| Medical condition: High-risk prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002217-35 | Sponsor Protocol Number: AG348-C-010 | Start Date*: 2018-11-20 | |||||||||||
| Sponsor Name:Agios Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase 2, Open-Label, Multicenter Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Subjects With Non-Transfusion-Dependent Thalassemia | |||||||||||||
| Medical condition: Non-Transfusion-Dependent Thalassemia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2009-013459-31 | Sponsor Protocol Number: AT1001-011 | Start Date*: 2009-12-10 | |||||||||||
| Sponsor Name:Amicus Therapeutics, Inc. | |||||||||||||
| Full Title: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACODYNAMICS OF AT1001 IN PATIENTS WITH FABRY DISEASE AND AT1001-RESPONSIVE GLA MUTATIONS | |||||||||||||
| Medical condition: Fabry Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) FR (Completed) DE (Completed) NL (Completed) BE (Completed) ES (Completed) IT (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.